208459-22-7

Upstream product

• 349636-51-7 5-[4-(4-oxopiperidin-1-yl)benzylidene]thiazolidine-2,4-dione 
• 344604-91-7 5-[4-(4-oxopiperidin-1-yl)benzyl]thiazolidine-2,4-dione 
• 730984-83-5 (S)-4-(2,3-epoxypropoxy)phenol 

Relevant academic research and scientific papers

2-substituted thiazolidinones as beta-3 adrenergic receptor agonists

This invention provides compounds of Formula I having the structure wherein: A, X, Y, Z, R1, R2, R3, R4, R5, and R6are as defined hereinbefore or a pharmaceutically acceptable salt thereof, which are useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, and frequent urination; and are particularly useful in the treatment or inhibition of type II diabetes.

2,4-Thiazolidinediones as potent and selective human β3 agonists

Methylsulfonamide substituted 2,4-thiazolidinedione 22c is a potent (EC50 = 0.01 μM, IA = 1.19) and selective (more than 110-fold over β1 and β2 agonist activity) β3 agonist. This compound has also been proven to be active and selective in an in vivo mode.